Symbiox Investme

What does Symbiox Investme do?

Symbiox Investment & Trading Co Ltd is a Non Banking Financial Company focused on trading in investments and textiles, with a market cap of Rs 11 Cr and recent net sales of 1 Cr. The company has a P/E ratio of 11.00 and reported no net profit for the latest quarter ending March 2025.

Overview: <BR>Symbiox Investment & Trading Co Ltd operates in the Non Banking Financial Company (NBFC) sector, focusing on trading in investments and textiles.<BR><BR>History: <BR>The company was incorporated in May 1979. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 11 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.63% <BR>Price to Book: 0.36<BR><BR>Contact Details: <BR>Address: 7A Rani Rashmoni Road, Kolkata West Bengal: 700013 <BR>Tel: 91-33-32515833 <BR>Email: symbioxinvestment100@gmail.com <BR>Website: http://www.symbioxinvestment.org

Has Symbiox Investme declared dividend?

No Dividend History Available

Who are the peers of the Symbiox Investme?

Symbiox Investme's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises. Symbiox Investme has below average management risk and capital structure, with a 1-year return of 25.00%.

Peers: The peers of Symbiox Investme are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, Muthoot Finance, and the rest. Average management risk is found at Jio Financial, Nexus Surgical, BCL Enterprises, and the rest. Good management risk is noted at Shriram Finance, while below average management risk is present at Symbiox Investme and Prism Medico. Growth is excellent at Jio Financial, while good growth is seen at Bajaj Finance, Cholaman.Inv.&Fn, and BCL Enterprises. Average growth is noted at Symbiox Investme, Shriram Finance, Nexus Surgical, and the rest, while below average growth is present at Prism Medico. Excellent capital structure is observed at Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Nexus Surgical, and BCL Enterprises, while good capital structure is noted at Cholaman.Inv.&Fn, and below average capital structure is present at Symbiox Investme and Prism Medico.<BR><BR>Return Snapshot: Bajaj Finance has the highest 1-year return at 30.45%, while Jio Financial has the lowest at -20.18%. Symbiox Investme's 1-year return is 25.00%, which is significantly higher than Jio Financial's but lower than Bajaj Finance's. Additionally, Libord Securitie and Prism Medico have negative six-month returns.

What is the technical trend for Symbiox Investme?

As of June 4, 2025, Symbiox Investme's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly MACD, bearish monthly MACD, bullish Bollinger Bands, and conflicting KST momentum.

As of 4 June 2025, the technical trend for Symbiox Investme has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating some short-term strength but overall uncertainty. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds to the mixed outlook. The KST shows bearish momentum on the weekly but bullish on the monthly, further contributing to the indecisive trend. Overall, the technical indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Who are in the management team of Symbiox Investme?

As of March 2022, the management team of Symbiox Investme includes Mina Devi Agarwal, Samit Ray, Mahavir Verma, Bappa Mitra, Rajkumari Naskar, Nitesh Poddar, and Khushboo Pitti, who serve in various executive and independent director roles.

As of March 2022, the management team of Symbiox Investme includes the following individuals:<BR><BR>1. Mina Devi Agarwal - Independent Director<BR>2. Samit Ray - Executive Director<BR>3. Mahavir Verma - Executive Director<BR>4. Bappa Mitra - Independent Director<BR>5. Rajkumari Naskar - Additional Independent Director<BR>6. Nitesh Poddar - Independent Director<BR>7. Khushboo Pitti - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company's governance and management structure.

Who are the top shareholders of the Symbiox Investme?

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited with 3.2%, Logihaze Solutions Private Limited at 2.47%, and individual investors holding 82.07%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited, which holds the highest promoter stake at 3.2%. The highest public shareholder is Logihaze Solutions Private Limited, with a holding of 2.47%. Additionally, individual investors collectively own a significant 82.07% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Symbiox Investme?

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, with Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, classifying it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

When is the next results date for Symbiox Investme?

Symbiox Investme will declare its results on 12 November 2025.

Symbiox Investme is scheduled to declare its results on 12 November 2025.

How has been the historical performance of Symbiox Investme?

Symbiox Investme's historical performance from March 2014 to March 2015 showed increased net sales and operating income, but profitability declined, resulting in a loss after tax and reduced margins. Despite improved cash flow and asset growth, the company faced challenges in maintaining profitability.

Answer:<BR>The historical performance of Symbiox Investme shows a mixed trend over the years, particularly between March 2014 and March 2015.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2015, Symbiox Investme reported net sales of 1.46 Cr, a significant increase from 0.28 Cr in March 2014. The total operating income also rose to 1.46 Cr from 0.28 Cr, reflecting improved business activity. However, total expenditure increased to 1.44 Cr from 0.27 Cr, leading to an operating profit (PBDIT) of 0.02 Cr, slightly up from 0.01 Cr in the previous year. Despite this, the profit before tax remained low at 0.02 Cr, compared to 0.01 Cr in March 2014. The company faced a loss in profit after tax, reporting -0.09 Cr in March 2015, down from a profit of 0.01 Cr in the prior year. The earnings per share (EPS) also declined to -0.03 from 0.01. The operating profit margin decreased to 1.58% from 4.23%, while the profit after tax margin fell to -6.11% from 5.28%. On the balance sheet, total assets were reported at 31.97 Cr in March 2025, showing a slight increase from 31.84 Cr in March 2024. The company maintained no long-term borrowings and reported a book value per share of 10.14 in March 2025, up from 10.08 in March 2024. Cash flow from operating activities improved to 3.00 Cr in March 2025, reversing a negative trend from the previous year. Overall, while there were increases in sales and operating income, the company struggled with profitability and margins during this period.

Is Symbiox Investme overvalued or undervalued?

As of December 4, 2025, Symbiox Investme is considered very expensive and overvalued, with a negative PE ratio of -872.92 and a year-to-date return of -48.52%, significantly underperforming compared to its peers and the Sensex.

As of 4 December 2025, the valuation grade for Symbiox Investme has moved from risky to very expensive, indicating a significant deterioration in its perceived value. The company is currently overvalued, with a PE ratio of -872.92, an EV to EBIT ratio of 5.40, and a Price to Book Value of 0.27. These ratios highlight the company's struggles, particularly with a negative PE ratio and a concerning return on equity of -0.03%.<BR><BR>In comparison to its peers, Symbiox Investme stands out unfavorably. For instance, Bajaj Finance has a PE ratio of 34.9, while Life Insurance boasts a much more attractive PE of 10.85. The stark contrast in valuation metrics suggests that Symbiox is not only overvalued but also significantly underperforming relative to its industry peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -48.52% compared to the Sensex's positive return of 9.12%. This further reinforces the notion that Symbiox Investme is not a favorable investment at this time.

Are Symbiox Investment & Trading Co Ltd latest results good or bad?

Symbiox Investment & Trading Co Ltd's latest results are concerning, showing a 33.3% decline in annual sales to ₹2.00 crores and zero net profit, alongside a poor return on equity of 0.85% and a 1-year stock return of -52.79%. Overall, these indicators suggest significant challenges and a negative trend for the company.

Symbiox Investment & Trading Co Ltd's latest results are concerning and indicate a negative trend. For FY25, the company reported annual sales of ₹2.00 crores, which represents a significant decline of 33.3% year-on-year from ₹3.00 crores in FY24. This decline highlights a lack of revenue stability and growth.<BR><BR>Moreover, the company has consistently struggled with profitability, reporting zero net profit across multiple fiscal years. The average return on equity (ROE) is a dismal 0.85%, indicating weak capital efficiency. Additionally, the stock has severely underperformed, with a 1-year return of -52.79%, contrasting sharply with the Sensex's gain of 7.07% during the same period.<BR><BR>The financial performance reflects persistent stagnation, with no meaningful operational scale or strategic direction. The absence of institutional investors and minimal promoter holding further raises concerns about management's commitment and the company's future prospects.<BR><BR>Overall, the latest results can be characterized as bad, with multiple red flags indicating significant challenges for the company moving forward.

Should I buy, sell or hold Symbiox Investment & Trading Co Ltd?

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 08-Feb, Symbiox Investment & Trading Co Ltd's stock price has risen to 2.03, reflecting a 6.84% increase, driven by strong investor interest and relative performance. However, despite short-term gains, the stock has poor long-term performance with significant negative returns over the past year and three years.

As of 08-Feb, Symbiox Investment & Trading Co Ltd is experiencing a rise in its stock price, currently at 2.03, which reflects an increase of 0.13 or 6.84%. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 6.22% today, indicating strong relative performance. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 72.01% against the 5-day average, suggesting heightened interest from investors.<BR><BR>In the short term, the stock has shown positive returns, with a 1-week increase of 9.73% and a 1-month increase of 18.02%. This contrasts sharply with the broader market, as the Sensex has only increased by 1.59% over the same week and decreased by 1.74% over the past month. However, it is important to note that despite these short-term gains, the stock has a poor long-term performance, with a 1-year return of -52.79% and a 3-year return of -66.56%. <BR><BR>The stock's current price is higher than its 5-day and 20-day moving averages, which may also contribute to the perception of upward momentum. However, it remains below its longer-term moving averages, indicating potential volatility. Overall, while the stock is rising in the short term due to increased investor interest and relative performance, its long-term fundamentals remain weak, characterized by negative EBITDA and a low return on equity.

Which are the latest news on Symbiox Investme?